Page last updated: 2024-09-05

sb 203580 and telmisartan

sb 203580 has been researched along with telmisartan in 2 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (telmisartan)	Trials (telmisartan)	Recent Studies (post-2010) (telmisartan)
3,489	4	1,137	1,930	480	1,038

Protein Interaction Comparison

Protein	Taxonomy	telmisartan (IC50)
Cytochrome P450 2C9	Homo sapiens (human)	0.42
Type-1 angiotensin II receptor	Homo sapiens (human)	0.0179
Type-2 angiotensin II receptor	Homo sapiens (human)	0.0003
Cytochrome P450 2J2	Homo sapiens (human)	0.5
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	1.2589
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	1.8621

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Akiyoshi, Y; Miyamoto, S; Morishima, M; Ono, K; Wang, Y	1

Other Studies

2 other study(ies) available for sb 203580 and telmisartan

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Telmisartan, an angiotensin II type 1 receptor antagonist, attenuates T-type Ca2+ channel expression in neonatal rat cardiomyocytes. European journal of pharmacology, 2009, May-01, Volume: 609, Issue:1-3 Topics: Action Potentials; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Benzimidazoles; Benzoates; Calcium Channels, T-Type; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Electrophysiology; Extracellular Signal-Regulated MAP Kinases; F-Box Proteins; Flavonoids; Gene Expression Regulation; Heart Rate; Imidazoles; JNK Mitogen-Activated Protein Kinases; Membrane Potentials; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Patch-Clamp Techniques; Pyridines; Rats; Rats, Wistar; RNA, Messenger; Telmisartan; Tetrazoles; Time Factors; Valine; Valsartan; Zebrafish Proteins	2009

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

Telmisartan, an angiotensin II type 1 receptor antagonist, attenuates T-type Ca2+ channel expression in neonatal rat cardiomyocytes.

European journal of pharmacology, 2009, May-01, Volume: 609, Issue:1-3

Topics: Action Potentials; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Benzimidazoles; Benzoates; Calcium Channels, T-Type; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Electrophysiology; Extracellular Signal-Regulated MAP Kinases; F-Box Proteins; Flavonoids; Gene Expression Regulation; Heart Rate; Imidazoles; JNK Mitogen-Activated Protein Kinases; Membrane Potentials; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Patch-Clamp Techniques; Pyridines; Rats; Rats, Wistar; RNA, Messenger; Telmisartan; Tetrazoles; Time Factors; Valine; Valsartan; Zebrafish Proteins

2009